ASX:ATX Amplia Therapeutics (ATX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Amplia Therapeutics Stock (ASX:ATX) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Get Amplia Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume77,249 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.Read More… Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Receive ATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATX Stock News HeadlinesAmplia CEO co-recipient of 2024 Prime Minister’s Prize for InnovationOctober 9, 2024 | msn.comAmplia Therapeutics’ Narmafotinib Gets Fast-track Designation from FDASeptember 26, 2024 | msn.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 29, 2024 | Paradigm Press (Ad)Amplia Therapeutics Ltd: FDA Fast Track Designation For Narmafotinib In Advanced Pancreatic CancerSeptember 20, 2024 | finanznachrichten.deMoneyTalks: Pengana’s James McDonald reveals his top three ASX biotechsSeptember 19, 2024 | msn.comAmplia Therapeutics Ltd INNMFAugust 16, 2024 | morningstar.com5 Pharma & Biotech Stocks on the move in JulyAugust 12, 2024 | msn.comASX Health Stocks: Amplia sees new success in pancreatic cancer trialAugust 6, 2024 | msn.comSee More Headlines ATX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Amplia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplia Therapeutics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and VelocityShares 1x Long VSTOXX Futures ETN (EVIX). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:ATX CUSIPN/A CIKN/A Webwww.ampliatx.com Phone61 2 8003 3650FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,500,000.00 Net Margins-101.14% Pretax MarginN/A Return on Equity-33.05% Return on Assets-17.04% Debt Debt-to-Equity Ratio13.90 Current Ratio1.98 Quick Ratio5.05 Sales & Book Value Annual Sales$4.45 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.88 Book ValueA$0.06 per share Price / BookN/AMiscellaneous Outstanding Shares274,800,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.72 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (ASX:ATX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.